RS001 cell therapy for relapsed B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a new cell therapy called RS001 for people with certain B-cell blood cancers (lymphoma or leukemia) that haven't responded to other treatments. It aims to see if this personalized therapy can help when standard options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a B-cell lymphoma (like DLBCL) or B-cell acute lymphoblastic leukemia that has come back or hasn't responded to at least two standard treatments.
- Your cancer cells test positive for CD19, a specific protein on the surface of these cells.
- You are between 18 and 75 years old and in fairly good health (able to do daily activities, with adequate organ function).
- You haven't received certain prior therapies like CAR-T or a stem cell transplant within a specific time frame.
- You do not have active infections like hepatitis B, C, or HIV, or other unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (RJMty19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. It aims to see if the therapy is safe and effective.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This early-stage trial tests a new cell therapy called GI001 for patients with B-cell lymphomas or leukemias that have come back or stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
This early-stage trial tests a new drug called HRS-1635 in patients with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to previous treatment. The goal is to find the right dose and understand how well and safely the drug works.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.